CS
ENTA icon

Credit Suisse’s Enanta Pharmaceuticals ENTA Stock Holding History

Credit Suisse’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-28,446
Closed -$318K – 3083
2023
Q3 		$318K Sell
28,446
-5,176
-15% -$83.4K ﹤0.01% 2912
2023
Q2 		$720K Buy
33,622
+5,147
+18% +$152K ﹤0.01% 2598
2023
Q1 		$1.15M Buy
28,475
+5
+0% +$239 ﹤0.01% 2240
2022
Q4 		$1.32M Buy
28,470
+702
+3% +$32K ﹤0.01% 2143
2022
Q3 		$1.44M Buy
27,768
+3,853
+16% +$225K ﹤0.01% 2065
2022
Q2 		$1.13M Buy
23,915
+2,531
+12% +$137K ﹤0.01% 2305
2022
Q1 		$1.52M Sell
21,384
-197
-0.9% -$12.8K ﹤0.01% 2267
2021
Q4 		$1.61M Sell
21,581
-784
-4% -$61.5K ﹤0.01% 2952
2021
Q3 		$1.27M Sell
22,365
-1,223
-5% -$60.5K ﹤0.01% 3154
2021
Q2 		$1.04M Sell
23,588
-1,319
-5% -$64.6K ﹤0.01% 3356
2021
Q1 		$1.23M Sell
24,907
-12,930
-34% -$645K ﹤0.01% 3190
2020
Q4 		$1.59M Buy
37,837
+2,892
+8% +$127K ﹤0.01% 3000
2020
Q3 		$1.6M Buy
34,945
+386
+1% +$18.7K ﹤0.01% 2590
2020
Q2 		$1.74M Buy
34,559
+20,307
+142% +$1.05M ﹤0.01% 2499
2020
Q1 		$734K Sell
14,252
-7,580
-35% -$404K ﹤0.01% 2894
2019
Q4 		$1.35M Buy
21,832
+2,138
+11% +$133K ﹤0.01% 2921
2019
Q3 		$1.18M Sell
19,694
-2,873
-13% -$213K ﹤0.01% 2900
2019
Q2 		$1.91M Buy
22,567
+1,132
+5% +$102K ﹤0.01% 2490
2019
Q1 		$2.05M Sell
21,435
-6,065
-22% -$544K ﹤0.01% 2351
2018
Q4 		$1.95M Sell
27,500
-4,387
-14% -$336K ﹤0.01% 2261
2018
Q3 		$2.72M Buy
31,887
+1,244
+4% +$125K ﹤0.01% 2128
2018
Q2 		$3.55M Buy
30,643
+1,849
+6% +$184K ﹤0.01% 1997
2018
Q1 		$2.33M Buy
28,794
+216
+0.8% +$16.6K ﹤0.01% 2297
2017
Q4 		$1.68M Sell
28,578
-3,416
-11% -$171K ﹤0.01% 2578
2017
Q3 		$1.5M Buy
31,994
+3,343
+12% +$134K ﹤0.01% 2794
2017
Q2 		$1.03M Sell
28,651
-17,807
-38% -$570K ﹤0.01% 2676
2017
Q1 		$1.43M Buy
46,458
+11,516
+33% +$359K ﹤0.01% 2600
2016
Q4 		$1.17M Buy
34,942
+7,015
+25% +$201K ﹤0.01% 2898
2016
Q3 		$744K Buy
27,927
+362
+1% +$8.41K ﹤0.01% 3190
2016
Q2 		$607K Sell
27,565
-6,322
-19% -$165K ﹤0.01% 3298
2016
Q1 		$995K Buy
33,887
+16,971
+100% +$472K ﹤0.01% 2728
2015
Q4 		$558K Buy
16,916
+806
+5% +$26.3K ﹤0.01% 3290
2015
Q3 		$581K Sell
16,110
-29,000
-64% -$1.25M ﹤0.01% 3286
2015
Q2 		$2.03M Buy
45,110
+14,732
+48% +$573K ﹤0.01% 2546
2015
Q1 		$929K Buy
30,378
+11,765
+63% +$458K ﹤0.01% 3031
2014
Q4 		$947K Sell
18,613
-475
-2% -$21.3K ﹤0.01% 3175
2014
Q3 		$755K Buy
19,088
+483
+3% +$19.3K ﹤0.01% 3305
2014
Q2 		$802K Buy
18,605
+8,007
+76% +$305K ﹤0.01% 3483
2014
Q1 		$424K Buy
10,598
+937
+10% +$34K ﹤0.01% 3836
2013
Q4 		$264K Buy
+9,661
New +$234K ﹤0.01% 4165

Other funds holding ENTA

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Credit Suisse's ENTA Position: Q4 2023 in Review

Credit Suisse sold out of Enanta Pharmaceuticals (ENTA) in Q4 2023, closing a stake of 28,446 shares — an estimated $318K sold.

Credit Suisse first reported a position in ENTA in Q4 2013 and held it in 40 quarters. The position peaked at $3.55M in Q2 2018. 106 funds tracked by Wall St. Rank hold ENTA as of Q4 2023.

  • Credit Suisse reported no remaining Enanta Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 28,446 Enanta Pharmaceuticals shares in Q4 2023, an estimated $318K.
  • Credit Suisse first reported a position in Enanta Pharmaceuticals in Q4 2013 and held it in 40 quarters.
  • Credit Suisse's Enanta Pharmaceuticals position peaked at $3.55M in Q2 2018.
  • 106 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.